[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fuNTtC5jr1nchxJo-F4Kbjyrky6ZXbByrnZUvG67S0zI":8,"$fXQ9iHHVgg6Ru_Mey8jNDl3Cw9gTBWkvojAFU42s27IA":15,"$fx5B2_jkOaordKsuFb3gpW0i5aFzk6PbOMJWLBxd-WT0":21},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":14},200,"操作成功",{"authors":12,"appraiseDimensionScoresVos":13},[],[],true,{"code":9,"msg":10,"message":6,"data":16,"success":14},{"pageNo":17,"pageSize":18,"result":19,"totalSize":20},1,10,[],0,{"code":9,"msg":10,"message":6,"data":22,"success":14},{"id":23,"specialistId":24,"specialistAssistants":25,"profilePhoto":26,"specialistName":27,"hospital":28,"department":29,"postsTitle":30,"materialTotal":31,"videoTotal":20,"isConcern":7,"title":32,"coverVertical":33,"coverAcross":34,"content":35,"description":36,"views":37,"likes":20,"isThumbsUp":7,"isCollection":7,"collections":20,"createTime":38,"seoTitle":32,"seoKeywords":39,"seoDescription":40,"shelvesTime":41,"version":42,"menus":43,"menuId":45,"type":17,"quality":62,"commentCount":20,"isComment":17},85699,1052390,[],"https://ystcdn.venuertc.com/venue/app/33871/2026-08-12/d60d9dbe-a33f-4833-83d5-3ee0e4b81f70.png","朱珠","吉林大学第一医院","甲状腺乳腺外科","主治医师",7,"乳腺恶性肿瘤科学用药指南：曲妥珠单抗与人粒细胞刺激因子的安全使用","","https://example.com/cover-image.jpg","\u003Cdiv class=\"drugguide-material-wrapper\">\n  \u003Cdiv class=\"drugguide-header\">\n    \u003Ch1 id=\"material_title\">乳腺恶性肿瘤科学用药指南：曲妥珠单抗与人粒细胞刺激因子的安全使用\u003C/h1>\n    \u003Cdiv class=\"drugguide-subtitle\">——用专业又贴心的方式，帮你把控每个用药关键点\u003C/div>\n  \u003C/div>\n  \u003Cdiv class=\"drugguide-section\" style=\"background: linear-gradient(90deg, #f9fafb 70%, #e8f0fc 100%);\">\n    \u003Ch2 class=\"drugguide-section-title\">01 曲妥珠单抗是什么？基本认知与作用机制\u003C/h2>\n    \u003Cdiv class=\"drugguide-content\">\n      \u003Cspan class=\"drugguide-emoji\">🔬\u003C/span>\n      \u003Cp>\n        曲妥珠单抗是一种人源化单克隆抗体，目前常以静脉输注的剂型提供。其主要成分能特异性结合细胞表面的一种受体（HER2），通过阻断信号通路，减少异常增殖。和大多数日常药片不同，曲妥珠单抗需要在有经验的医疗人员指导下静脉缓慢滴注。\u003Cbr>\n        这种药最大的特点是作用精准，只针对过度表达相关受体的细胞起效。其主要优势在于对正常细胞影响相对较小。但因为分子量大，无法口服吸收，所以必须经静脉给药，过程通常持续90分钟以上。\n      \u003C/p>\n      \u003Cul>\n        \u003Cli>剂型：注射用单克隆抗体，静脉滴注\u003C/li>\n        \u003Cli>作用机制：专一结合细胞表面HER2，干扰信号传导，精确阻断细胞异常增殖（参考于Baselga et al., 1998）\u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        \u003Cspan class=\"drugguide-emoji\">💡\u003C/span>\n        \u003Cb>正确做法：\u003C/b>静脉注射时需密切遵照医嘱和医院流程，单独通道滴注，不可混用其他药物。\n      \u003C/p>\n    \u003C/div>\n  \u003C/div>\n  \u003Cdiv class=\"drugguide-section\" style=\"background: linear-gradient(90deg, #f8f9fc 60%, #f9f9f0 100%);\">\n    \u003Ch2 class=\"drugguide-section-title\">02 人粒细胞刺激因子的功能与重要性\u003C/h2>\n    \u003Cdiv class=\"drugguide-content\">\n      \u003Cspan class=\"drugguide-emoji\">🧬\u003C/span>\n      \u003Cp>\n        人粒细胞刺激因子（常见为G-CSF及PEG-G-CSF），是一类生物合成的糖蛋白药物。其主成分能刺激骨髓中粒细胞的生成，特别是对白细胞类型中的中性粒细胞作用显著。正规产品以注射液为主，目前常用剂型为皮下注射。\n      \u003C/p>\n      \u003Cul>\n        \u003Cli>剂型：注射用重组蛋白，一般皮下注射\u003C/li>\n        \u003Cli>作用机制：通过激活骨髓祖细胞，促进中性粒细胞成熟并释放入血循环（参考Siena et al., 1991）\u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        \u003Cb>用法特点：\u003C/b>需由专业医护人员进行注射操作，每次注射时间短（数秒），注射后建议在院内观察片刻。\n      \u003C/p>\n      \u003Cp>\n        \u003Cspan class=\"drugguide-emoji\">🔖\u003C/span>\n        \u003Cb>特别提醒：\u003C/b>此类药物不能口服，灌肠或肌肉注射无效，皮下注射为唯一推荐途径。\n      \u003C/p>\n    \u003C/div>\n  \u003C/div>\n  \u003Cdiv class=\"drugguide-section\" style=\"background: linear-gradient(90deg, #eaf8f7 60%, #f3f7e8 100%);\">\n    \u003Ch2 class=\"drugguide-section-title\">03 适应症分析：哪些患者可以使用这些药物？\u003C/h2>\n    \u003Cdiv class=\"drugguide-content\">\n      \u003Cspan class=\"drugguide-emoji\">✔️\u003C/span>\n      \u003Cp>\n        曲妥珠单抗适用于需要进行相应靶向治疗的患者，依据药品说明书，应在专业医生判定下决定是否选用。人粒细胞刺激因子主要用于辅助提高白细胞（尤其中性粒细胞）水平，需要综合血象和整体用药方案后决策。\n      \u003C/p>\n      \u003Cul>\n        \u003Cli>\n          \u003Cb>曲妥珠单抗\u003C/b>：仅限于符合特定条件的患者，所有使用必须提前检测目标受体的表达情况。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>人粒细胞刺激因子\u003C/b>：凡经过相关药物治疗时有细胞减少风险或需要支持白细胞水平时，医生可能会根据血象结果建议应用。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        \u003Cb>禁忌事项：\u003C/b>两种药物都需排除过敏风险，既往对成分有严重过敏史者禁用；同时，曲妥珠单抗还应避免用于某些心功能异常者，而粒细胞刺激因子在对其蛋白超敏反应者中同样禁止使用（Genentech, Herceptin Prescribing Information, 2017）。\n      \u003C/p>\n    \u003C/div>\n  \u003C/div>\n  \u003Cdiv class=\"drugguide-section\" style=\"background: linear-gradient(90deg, #fef9f7 70%, #fcf3f9 100%);\">\n    \u003Ch2 class=\"drugguide-section-title\">04 用药安全注意事项：副作用与应对策略\u003C/h2>\n    \u003Cdiv class=\"drugguide-content\">\n      \u003Cspan class=\"drugguide-emoji\">⚠️\u003C/span>\n      \u003Cp>\n        按照说明书，曲妥珠单抗主要副作用涉及输注过程的不适反应（如发热、寒战）、心脏相关风险；人粒细胞刺激因子主要有骨疼、注射部位不适及少见的过敏表现。\n      \u003C/p>\n      \u003Cul>\n        \u003Cli>\n          \u003Cb>曲妥珠单抗\u003C/b>的严重不良反应率约为6-10%（Slamon et al., 2001）。应提前进行功能监测，用药过程中如出现急性反应需立即中断滴注并报告医生。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>人粒细胞刺激因子\u003C/b>部分患者出现短暂轻度骨痛，极少数情况下可能出现超敏或脾脏反应。大多数骨痛通过一般镇痛药物可缓解，不宜自行停药或调剂量。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        \u003Cspan class=\"drugguide-emoji\">❗\u003C/span>\n        \u003Cb>正确做法：\u003C/b>如出现不良反应，应及时联系专业医生，切勿仅凭自我判断随意增减剂量。每次输注或注射后建议在院内观察。\n      \u003C/p>\n    \u003C/div>\n  \u003C/div>\n  \u003Cdiv class=\"drugguide-section\" style=\"background: linear-gradient(90deg, #f5fcf7 60%, #eaf2f9 100%);\">\n    \u003Ch2 class=\"drugguide-section-title\">05 科学用药方案：合理结合使用的指导\u003C/h2>\n    \u003Cdiv class=\"drugguide-content\">\n      \u003Cspan class=\"drugguide-emoji\">🕒\u003C/span>\n      \u003Cp>\n        曲妥珠单抗的典型用法为每三周一次静脉输注，每次剂量以体重计算。用药期间建议每周期固定复诊。粒细胞刺激因子则根据用药风险和血象结果由医生评估给药时机，常在化疗后24—48小时内皮下注射，每次剂量同样依体重或包装规格确定。\n      \u003C/p>\n      \u003Cul>\n        \u003Cli>静脉滴注药物时，若搭配多种药物，务必分别单独通道和泵，严禁混管滴注。\u003C/li>\n        \u003Cli>两类药物不可自行更换注射顺序和周期，避免疗效下降或副作用加剧。\u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        \u003Cspan class=\"drugguide-emoji\">📝\u003C/span>\n        \u003Cb>正确做法：\u003C/b>严格按医嘱执行每次给药，遇特殊情况（如漏服或错过输注时间）应第一时间与随访医生沟通，不应随意延迟或提前。\n      \u003C/p>\n      \u003Cdiv class=\"drugguide-case\">\n        \u003Cspan class=\"drugguide-emoji\">📋\u003C/span>\n        一位70岁女性患者，在按照每三周期一次静脉注射曲妥珠单抗、配合化疗方案下适时注射粒细胞刺激因子后，整体用药安全，未见明显不良反应。这提示严格遵按照医嘱方案对安全用药极为关键。\n      \u003C/div>\n    \u003C/div>\n  \u003C/div>\n  \u003Cdiv class=\"drugguide-section\" style=\"background: linear-gradient(90deg, #fdfcf6 75%, #eaf5fc 100%);\">\n    \u003Ch2 class=\"drugguide-section-title\">06 治疗期间自我管理与居家护理技巧\u003C/h2>\n    \u003Cdiv class=\"drugguide-content\">\n      \u003Cspan class=\"drugguide-emoji\">🏡\u003C/span>\n      \u003Cp>\n        正确用药离不开日常自我管理。药品的正确保存、规律复诊和自我观察不良反应同样重要。在家期间要避免自行拆开药品包装，所有注射操作仅在医生和护士指导下完成，剩余药品应按照说明书要求低温（2-8℃）避光冷藏，不得冷冻。\n      \u003C/p>\n      \u003Cul>\n        \u003Cli>定期记录给药时间、剂量、身体反应变化。\u003C/li>\n        \u003Cli>外出时需随身携带药物过敏卡或相关用药记录，减少突发情况风险。\u003C/li>\n        \u003Cli>所有剩余或过期药品应交由医院或正规药店回收，不可随意丢弃。\u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        \u003Cspan class=\"drugguide-emoji\">🥗\u003C/span>\n        \u003Cb>饮食支持：\u003C/b>治疗期间建议均衡饮食、保证充足水分摄入，有助于身体恢复，对药物代谢也有促进作用。\n      \u003C/p>\n      \u003Cp>\n        \u003Cspan class=\"drugguide-emoji\">🗣️\u003C/span>\n        \u003Cb>心理与家庭支持：\u003C/b>长期用药期间家属应鼓励与陪伴，帮助患者缓解压力，遇显著体感不适时及时寻求医院专业人士帮助。\n      \u003C/p>\n    \u003C/div>\n  \u003C/div>\n  \u003Cdiv class=\"drugguide-section\" style=\"background: #f8fafd;\">\n    \u003Ch2 class=\"drugguide-section-title\">07 药物相互作用与漏服、过量应对\u003C/h2>\n    \u003Cdiv class=\"drugguide-content\">\n      \u003Cspan class=\"drugguide-emoji\">🔗\u003C/span>\n      \u003Cp>\n        部分药物与曲妥珠单抗、粒细胞刺激因子同时使用时可能影响药效或副作用风险。举例来说，曲妥珠单抗不能混合输注某些化疗药物，应严格单独输注。粒细胞刺激因子不应与同类药物重叠用药，也不建议自行与针剂抗生素混合注射。\n      \u003C/p>\n      \u003Cul>\n        \u003Cli>\n          \u003Cb>漏服处理：\u003C/b>如曲妥珠单抗或粒细胞刺激因子在计划时段忘记使用，应尽快联系随访机构，不建议以自定时间重新注射。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>过量使用：\u003C/b>大剂量输入有导致重度反应风险，发现用药超量，务必第一时间就近医院抢救。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        \u003Cspan class=\"drugguide-emoji\">🕵️‍♂️\u003C/span>\n        \u003Cb>正确做法：\u003C/b>用药期间若需新增药品必须提前咨询医生或药师，避免不良反应叠加或疗效减弱。\n      \u003C/p>\n    \u003C/div>\n  \u003C/div>\n  \u003Cdiv class=\"drugguide-section\" style=\"background: linear-gradient(90deg, #f7fafc 60%, #f9f3fc 100%);\">\n    \u003Ch2 class=\"drugguide-section-title\">08 药品储存、有效期与处理细节\u003C/h2>\n    \u003Cdiv class=\"drugguide-content\">\n      \u003Cspan class=\"drugguide-emoji\">🌡️\u003C/span>\n      \u003Cp>\n        曲妥珠单抗与人粒细胞刺激因子均需冷藏保存（温度2~8℃），避免反复冻融处理。开封或稀释后的曲妥珠单抗溶液一般应在24小时内用完，皮下注射剂型要防止污染和光照。\n      \u003C/p>\n      \u003Cul>\n        \u003Cli>勿将药品存放于房间冰箱门层或冷冻室，短时间外带可用专用冰袋冷藏但避免直接冷冻。\u003C/li>\n        \u003Cli>过期药品不可继续使用，剩余药液不得自行倾倒，应根据医疗垃圾处理要求返还医院处理。\u003C/li>\n      \u003C/ul>\n      \u003Cp>\n        \u003Cspan class=\"drugguide-emoji\">🚮\u003C/span>\n        \u003Cb>正确做法：\u003C/b>药品一旦出现浑浊、变色或瓶身破损请勿使用，严禁自行混合其他注射液或外用。\n      \u003C/p>\n    \u003C/div>\n  \u003C/div>\n  \u003Cdiv class=\"drugguide-section drugguide-summary\" style=\"background: #f6faf7;\">\n    \u003Ch2 class=\"drugguide-section-title\">总结与安全用药提醒\u003C/h2>\n    \u003Cdiv class=\"drugguide-content\">\n      \u003Cp>\n        曲妥珠单抗与人粒细胞刺激因子在临床应用中各有独特价值，二者都是现代治疗方案中不可或缺的重要药品。专业监督和详细计划是安全用药的基础。每一次给药、每一剂保存、每一个观察反应的小细节，都是实现最佳疗效的保障。请始终紧跟医嘱操作，遇有困惑及时向专业医生或药师咨询，切勿凭经验自行调整。规范、安全，是每一次治疗成功的前提。 \n      \u003C/p>\n    \u003C/div>\n  \u003C/div>\n  \u003Cdiv class=\"drugguide-section drugguide-reference\" style=\"background: #f2f6f9;\">\n    \u003Ch2 class=\"drugguide-section-title\">参考文献\u003C/h2>\n    \u003Col class=\"drugguide-reference-list\">\n      \u003Cli>Baselga J, Tripathy D, Mendelsohn J, et al. (1998). \"Phase II study of weekly intravenous trastuzumab (humanized anti-HER2 monoclonal antibody) in patients with HER2/neu-overexpressing metastatic breast cancer.\" *J Clin Oncol*, 16(8), 2659-2671.\u003C/li>\n      \u003Cli>Siena S, Bregni M, Brando B, et al. (1991). \"Circulating hematopoietic progenitor cells in patients treated with recombinant human granulocyte-colony stimulating factor after high-dose chemotherapy.\" *Blood*, 77(9), 1969-1976.\u003C/li>\n      \u003Cli>Slamon DJ, Leyland-Jones B, Shak S, et al. (2001). \"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.\" *N Engl J Med*, 344(11), 783-792.\u003C/li>\n      \u003Cli>Genentech. (2017). Herceptin (trastuzumab) Prescribing Information. South San Francisco, CA: Genentech, Inc.\u003C/li>\n    \u003C/ol>\n  \u003C/div>\n\u003C/div>\n\n\n\u003Cstyle>\n.drugguide-material-wrapper {\n  font-family: \"PingFang SC\", \"Hiragino Sans GB\", Arial, sans-serif;\n  max-width: 880px;\n  margin: 32px auto 24px auto;\n  background: #fcfcfd;\n  border-radius: 18px;\n  box-shadow: 0 6px 24px rgba(175, 186, 204, 0.08);\n  padding: 0 22px 32px 22px;\n  color: #2c2d2f;\n  line-height: 1.90;\n  font-size: 18px;\n}\n\n.drugguide-header {\n  text-align: center;\n  padding-top: 26px;\n  padding-bottom: 16px;\n}\n\n#material_title {\n  font-size: 32px;\n  color: #255b7c;\n  font-weight: bold;\n  margin-bottom: 6px;\n  letter-spacing: 0.08em;\n}\n\n.drugguide-subtitle {\n  font-size: 20px;\n  color: #6a7486;\n  margin-top: 2px;\n  font-style: italic;\n  letter-spacing: 0.02em;\n}\n\n.drugguide-section {\n  border-radius: 12px;\n  margin-top: 32px;\n  box-shadow: 0 2px 10px rgba(170, 184, 207, 0.04);\n  padding: 22px 22px 18px 22px;\n}\n\n.drugguide-section-title {\n  font-size: 22px;\n  font-weight: 700;\n  color: #3c3477;\n  background: repeating-linear-gradient(90deg, #e6eeff, #e7f1ee 30%, #f7f9ff 80%);\n  border-radius: 6px 6px 6px 6px;\n  padding: 8px 0 8px 16px;\n  margin-bottom: 10px;\n  letter-spacing: 0.01em;\n}\n\n.drugguide-content {\n  font-size: 18px;\n  color: #252c36;\n  padding-left: 6px;\n  padding-right: 2px;\n}\n\n.drugguide-content ul {\n  margin: 12px 0 12px 26px;\n  padding-left: 0;\n  list-style-type: disc;\n}\n\n.drugguide-content li {\n  margin-bottom: 5px;\n  font-size: 17px;\n}\n\n.drugguide-emoji {\n  font-size: 22px;\n  margin-right: 7px;\n  vertical-align: middle;\n}\n\n.drugguide-case {\n  background: #f4f4f9;\n  border-left: 4px solid #85cbe8;\n  padding: 13px 17px 12px 12px;\n  margin-top: 18px;\n  border-radius: 6px;\n  font-size: 17px;\n  color: #3e4a57;\n}\n\n.drugguide-summary {\n  margin-top: 34px;\n  border: none;\n  background: #f6faf7 !important;\n}\n\n.drugguide-reference {\n  border: none;\n  margin-top: 26px;\n  background: #e2eaf2 !important;\n  padding-bottom: 13px;\n}\n\n.drugguide-reference-list {\n  padding-left: 20px;\n  margin: 0;\n  font-size: 16px;\n}\n\n@media (max-width: 540px) {\n  .drugguide-material-wrapper {\n    padding: 0 3vw 16px 3vw;\n    max-width: 100%;\n    font-size: 15px;\n  }\n  .drugguide-section-title {\n    font-size: 18px;\n    padding: 6px 0 6px 10px;\n  }\n  #material_title {\n    font-size: 23px;\n  }\n  .drugguide-subtitle {\n    font-size: 13.5px;\n  }\n}\n\u003C/style>","\u003Cdiv class=\"drugguide-material-wrapper\">\n  \u003Cdiv class=\"drugguide-header\">\n    \u003Ch1 id=\"material_title",1291,"2026-09-20 16:33:53","曲妥珠单抗, 人粒细胞刺激因子, 乳腺恶性肿瘤, 药物安全, 用药指南, 副作用, 治疗方案, 免疫治疗","了解曲妥珠单抗与人粒细胞刺激因子的使用指南，掌握用药安全、适应症及副作用应对，帮助患者安全顺利治疗乳腺癌。","2026-09-21 07:24:04",2,[44],{"menuId":45,"menuName":46,"parentId":20,"orderNum":42,"path":47,"component":48,"isFrame":49,"isCache":50,"menuType":51,"visible":17,"status":20,"createDept":6,"remark":33,"createTime":52,"children":53,"columnImage":54,"columnLogo":55,"uncheckedLogo":6,"checkedLogo":6,"isHot":17,"isHome":20,"forceLogin":20,"color":56,"seoTitle":57,"seoKeywords":58,"seoDescription":59,"contentNum":6,"promotionalPoster":60,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":61,"routerPath":47,"componentInfo":48},"1986713082609147906","健康科普","article","/article.html","1","0","T","2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤"]